تاثیر پروبیوتیک بر بیماری گوارشی
محورهای موضوعی : میکروبیولوژی
سهیلا فدایی
1
(دانشگاه ازاد شهرکرد)
کلید واژه: پروبیوتیک, میکرواورگانیسم, فیزیولوژی, روتا ویروس, عدم تحمل لاکتوز,
چکیده مقاله :
پروبیوتیک ها گروهی از میکرواورگانیسم های مفید مستقر در روده هستند که در صورت مصرف تاثیر مثبتی به سلامت یا فیزلوژی میزبان دارند آنها می توانند فیزیولوژی روده را به طور مستقیم یا غیر مستقیم از طریق تعدیل اکوسیستم درونی تحت تاثیر قرار دهند نتایجی برای استفاده از پروبیوتیک ها به عنوان درمان اختلالات گوارشی نشان داده شده است عبارتند از ۱) استفاده از ساکارومایسس بولاردی Enterococcus faecium SF68 برای جلوگیری یا کوتاه کردن مدت اسهال مرتبط با انتی بیوتیک ۲) جلوگیری از s.boulardi که از اسهال مرتبط باClostridium difficil جلوگیری میکند. ۳) استفاده از شیرهای تخمیر شده حاوی Lactobacillus rhamnsousدر نوزادان مبتلا به انتریت روتا ویروس. ۲) جلوگیری از s.boulardi که از اسهال مرتبط باClostridium difficil جلوگیری میکند. ۳) استفاده از شیرهای تخمیرشده حاوی Lactobacillus rhamnsousدر نوزادان مبتلا به انتریت روتا ویروس. بنابراین نظر پژوهشگران ، مصرف پروبیوتیک ، موجب تعادل مجدد ترکیب میکروبی روده وتعدیل بیماریهای التهاب روده، گاستروانتریت ، عدم تحمل لاکتوز و اسهال مربوط به مصرف آنتی¬بیوتیک میشود از این رو مواد زیستی به عنوان راهکاری موثر در پیشگیری درمان بیماری شناخته میشود.
Probiotics are a group of beneficial microorganisms living in the gut, which when consumed have a positive effect on physiological health directly or indirectly through the modulation of the internal ecosystem influencing the results for the use of probiotics. Indicated as a treatment for gastrointestinal disorders are 1) the use of Saccharomyces boulardi Enteroccus faecium SF68 to prevent or shorten the duration of antibiotic-associated diarrhea, 2) the prevention of S. boulardi, which prevents Clostridium difficil-associated diarrhea. 3) Fermented milk contains Lactobacillus rhamnsousder for infants with rotavirus enteritis. Therefore, according to the researchers, the use of probiotics, the creation of microbial recombination of the intestines, gastroenteritis, lactose intolerance and diarrhea are related to the use of antibiotics from these biological substances as a treatment for diseases caused by chronic diseases.
1. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. 2002, pp. 111. Available online: https://www.who.into/foodsafety/fs_management/en/probiotic_guidelines.pdf (accessed on 16 March 2019).
2. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506-514. [CrossRef]
3. Johnston, B.C.; Lytvyn, L.; Lo, C.K.; Allen, S.J.; Wang, D.; Szajewska, H.; Miller, M,; Ehrhardt, S .; Sampalis, J.; Duman, D.G.; et al. Microbial preparations (probiotics) for the prevention of clostridium difficile infection in adults and children: An individual patient data meta-analysis of 6851 participants. Infect. Control Hosp. Epidemiol. 2018, 39, 771-781. [CrossRef]
4. Fuller R. Probiotics in man and animal. J Appl Bacteriol 1989; 66:365-78.
5. Marteau P, Pochart P, Bouhnik Y, Rambaud JC. Fate and effects of some transiting microorganisms in the human gastrointestinal tract. World Rev Nutr Diet 1993;74:1-21.
6. Scientific research monthly of Shahid Sadougi University of Medical Sciences and Health Services, Yazd spring 2018
7. de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J. Probiotics—compensation for lactase insuffi-ciency. Am J Clin Nutr 2001;73:421S-95.
8. Harms HK, Bertele-Harms RM, Bruer-Kleis D. Enzyme substitu-tion therapy with the yeast Saccharomyces cerevisiae in congenital sucrase-Isomaltase deficiency. N Engl J Med 1987;316:1306-9.
9. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870-6.
10. Corthier G. Antibiotic-associated diarrhea: treatments by living organism given by the oral route (probiotics). In: Fuller R, ed.
11. Ligny G. Le (railemen) par 1’U1tralevure des trubles intestinaux secondCaires a I’antibiotherapie. Etude en double aveugle et etude elinique simple. (Saccharomyces boulardii as a treatment for antibi-olic associated disorders. A double blind study.) Revuc Francaise de Gastroenterologie 1975;114:45-50 (in French).
12. Pearce JL, H amilton Jr. Controlled trial of orally administered lac-tobacilli in acute infantile diarrhea. J Pediatr 1974;84:261-2.
13. Mitra AK, Rabbaani GH. A double-blind, controlled trial of bioflorin (Streplococcus faecium SF68) in adults with acute diar-rhea due to Vibrio cholerae and enterotoxigenic Escherichia coli.
14. Raza S, Graham SM, Allen SJ, Sultana S, Cuevas L, Hart CA. Lac-tobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J 1995;14:107-11.
15. Pant AR, Graham SM, Allen SJ, et al. Lactobacillus GG and acute diarrhea in young children in the tropics. J Trop Pediatr 1996;42:162-5.
16. Guandalini S, Pensaene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000;30:54-60.
17. Kaila M, Isolauri E, Saxelin M, Arvilommi H, Vesikari T, Viable versus inactivated Lactobacillus strain GG in acute rotavirus diar-rhoea. Arch Dis Child 1995;72:51-3.
18. Bodilis JY. Etude controlee du Lacteol fort contre placebo et contre produit de reference dans les diarrhees aigues de l’adulte. (Lacteol versus placebo in acute adult diarrhea: a controlled study.) Medecine Actuelle 1983;10:232-5 (in French).
19. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feed-ing of Bifidobacterium bifidum and Streptococcus thermophiles to infants in hospital for prevention of diahrroea and shedding of rotavirus. Lancel 1994;344:1046-9.
20. Maupas JL, Champemont P, Delforge M. Traitement des colopathies fonctionnelles –Essai en double aveugle de l’ultra-levure. (Treatment of irritable bowel syndrome with Saccharomyces boulardii—a double-blind, placebo controlled study.) Medicine et Chirurgie Digestives 1983;12:77-9 (in French).
21. Halpern GM, Prindiville T, Blanckenburg M, Hisa T, Gerschwin ME. Treatment of irritable bowel syndrome with Lacteol fort: a ran-domized, double-blind, cross-over trial. Am J Gastroenterol 1996;91:1579-85.
22. Hentschel C, Bauer J, Dill N, et al. Complementary medicine in non-ulcer dyspepsia: is alternative medicine a real alternative? A randomized placebo –controlled double-blind clinical trial with two probiotic agents—Hylac@ and Hylac@ forte. Gastroenterology 1997;112:A146 (abstr).
23. Marteau, P., Boutron-Ruault, MC. (2002) Nutritional advantage of 16,. Probiotics and Prebiotics. Br.J.Nutr.;87:S153-S157.
24. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A mul-ticenter, randomized, double-blind placebo-controlled trail. Intens Care Med 1997;23:517-23.
25. Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial over-growth-related chronic diarrhea: a crossover , randomized trial. Gas-troenterology 1999;117:794-7.
26. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999:354:635-9.
27. Elmer GW, Moyer KA, Surawicz CM, Collier AC, Hooton TM, McFarland LV. Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and healthy volunteers receiving.
28. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology. 2009;7(11):1202-9.
29. Fabia R, Ar’Rajab A, Johansson ML, Willen R, Andersson R, p effect of exogenous administration of Lactobacillus reuteri R2LC and out fiber on acetic acid-induced colitis in the rat. Scand J Gas-troenterol 1993;28:155-62.
30. Mao Y, Nobaeck S, Kasravi B, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334-44.
31. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune with Lactobacillus GG. Ann Nutr Metab 1996;40:137-45.
32. Plein K, Hotz J.Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea—a pilot study. Z Gastroenterol 1993;31:129-34.
33. Campieri M, Gionchetti P, Probiotics in inflammatory bowel dis-ease: new insight to pathogenesis or a possible therapeutic alterna-tive? Gastroenterology 1999;116:1246-9.
34. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001;73:451S-5S.
35. Rafter JJ. The role of lactic acid bacteria in colon cancer prevention. Scand J Gastroenterol 1995;30:497-502.
36. Black FT, Andersen PL, Orskov J, et al. Prophylactic efficacy of lac-tobacilli on traveler’s diarrhea. Travel Med 1989;7:333-5. 42
37. Kollarritsch von H, Holst H, Grobara P, Wiedermann G. Prophylaxe des Reisediarrhoe mit Saccharomyces boulardii. (Prevention of trav-elers’ diarrhea by Saccharomyces boulardii. Results of a placebo-controlled double-blind study.) Fortschritte der Medizin 1993;111:153-6 (in German).
38. Kurt Fenster, Barbara Freeburg, Chris Hollard. The production and Delivery of probiotics: A Review of a practical Approach, 17 March 2019; published.
39. Parvez, S., Malik, K. A., Kang, S. A., and Kim, H. Y. (2006). Probiotics and their fermented food products are beneficial for health. Journal of Applied Microbiology,. 100(6), 1171-1185
40. Marco, M.L., Heeney, D., Binda, S., Cifelli, C. J., Cotter, P. D., Foligne, B., … and O’Toole, P. W. (2021). Health benefits of fermented foods: microbiota and beyond. Current Opinion ,in Biotechnology, 70, 109-114.
41. Andera Mesture, Rajalakshmi sathiya Narayanan, Deliana Rivas (2022):Role of probiotics in the management of Helicobacter Pylori.Dol:10.7759/cureus.26463.
42. Sanai, Marzieh. Yazdi, Mohammad Hossein. Mahdavi, Mahdi. (2022) Postbiotics: the new generation of probiotics. Journal of Alborz University of Medical Sciences, Volume: 11, Number: 4, Pages: 513-523
43. Santivarangkna, C.; Kulozik, U., Forest, P. Inactivation mechanisms of lactic acid starter cultures preserved by drying processes. J. Apple. Microbiol . 2008, 105, 1-13. [CrossRef] [PubMeD].